Market capitalization | $217.34m |
Enterprise Value | $359.03m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 0.80 |
P/S ratio (TTM) P/S ratio | 0.49 |
P/B ratio (TTM) P/B ratio | 5.29 |
Revenue growth (TTM) Revenue growth | -0.24% |
Revenue (TTM) Revenue | $446.55m |
EBIT (operating result TTM) EBIT | $504.00k |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
4 Analysts have issued a Accuray Incorporated forecast:
4 Analysts have issued a Accuray Incorporated forecast:
Jun '24 |
+/-
%
|
||
Revenue | 447 447 |
0%
0%
|
|
Gross Profit | 143 143 |
7%
7%
|
|
EBITDA | 6.41 6.41 |
17%
17%
|
EBIT (Operating Income) EBIT | 0.50 0.50 |
84%
84%
|
Net Profit | -16 -16 |
68%
68%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes cyberKnife and tomo therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.
Head office | United States |
CEO | Sandeep Chalke |
Founded | 1990 |
Website | www.accuray.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.